On December 7, 2025, "Huawei Data Storage" announced the official launch of the Huawei AI Data Platform for the healthcare sector. Built on the OceanStor A800 storage system, this AI data platform integrates three core technologies: knowledge generation and retrieval, memory extraction and recall, and UCM inference acceleration. It is designed to help West China Hospital's "Rui Bin 2" medical agent overcome the long-standing "iron triangle" bottleneck of balancing cost, quality, and accessibility in healthcare, thereby accelerating the implementation of intelligent solutions.
Ant Group's consumer-facing AI healthcare application "AQ" has been rebranded as "Ant Afu," marking a strategic brand upgrade. On November 8, 2025, during the World Internet Conference Wuzhen Summit, West China Hospital of Sichuan University and Ant Group formally entered into a strategic cooperation agreement. The collaboration will focus on chronic diseases such as respiratory conditions, jointly advancing scientific research, service system development, and the integration of innovation in "AI + healthcare" to empower and enhance primary care services.
A CITIC Securities research report highlights that the Ant Afu APP boasts three key strengths: structured multimodal precision consultation capabilities, enhanced user stickiness from long-term health data accumulation, and promising commercialization prospects through its integration with the Alibaba ecosystem. The report is optimistic that major internet firms, leveraging their AI product strength, mature ecosystems, and substantial marketing budgets, are poised to capture the market early, cultivate user acceptance of AI family doctors, and develop a national-level AI healthcare application that integrates medical consultation, health management, and healthcare consumption.
A Guojin Securities research note indicates that AI healthcare has entered a phase of accelerated commercialization, expressing continued confidence in companies that possess technological barriers, practical application capabilities, and clear paths to monetization. Such firms are expected to achieve rapid scaling and a fundamental improvement in profitability after crossing the critical threshold of technological and market maturity.
China Securities (CSC) points out that 2025 has seen continuous progress in domestic AI healthcare across policy, technology, product development, and application. Technological breakthroughs are evolving from single products to full-scenario chains, while applications are expanding from major hospitals down to primary care institutions and individuals. AI healthcare holds significant application value in numerous areas, including enhancing medical device functionality, interpreting test results, assisting clinical decision-making, and health management. It represents an essential innovation direction and competitive trend that healthcare enterprises and hospitals must prioritize. Driven by ongoing national policies and industry technological advancements, AI healthcare application scenarios are expected to accelerate their implementation. It is anticipated that other regions will subsequently introduce supportive policies, suggesting close attention to investment opportunities within the sector.
Relevant AI healthcare industry chain stocks in Hong Kong include: Yidu Tech (02158): As a leading domestic AI healthcare company, Yidu Tech was invited to the Henan Provincial Health Industry Development Conference and signed on as one of the first partners for the National AI Application Pilot Base (Healthcare direction). The company has recently made multiple advancements in AI healthcare innovation, including deep involvement in the Beijing healthcare sector's National AI Application Pilot Base, winning a Phase III clinical research project, and adding "Hui Min Bao" businesses in both Hebei and Guangzhou.
iFlytek Healthcare Technology (02506): A Southwest Securities research report states that the AI healthcare market offers substantial space for growth. iFlytek Healthcare Technology possesses its self-developed foundational large model, with performance ceilings continuously rising. As the AI healthcare company with the broadest industry coverage, it is considered the primary candidate to benefit from policy tailwinds and national-level projects, suggesting ongoing attention.
JD Health (06618): The company is consolidating its leading position in pharmaceutical e-commerce by expanding medical insurance payment coverage, broadening offline services, and deepening its布局 in AI healthcare applications.
ALI HEALTH (00241): The company is actively exploring AI applications in healthcare. Internally, AI is applied to optimize search in pharmaceutical e-commerce, enhance the supply chain for its owned pharmacies, manage self-operated products via AI hosting, and power intelligent customer service. Externally, it focuses on helping professional users improve efficiency, having launched an AI medical assistant named "Hydrogen Ion" for doctors, which is currently still in the product refinement stage.
Gushengtang (02273): As a leading provider of traditional Chinese medicine services, the company is developing "National Physician AI Avatars" and AI health assistants, steadily advancing its AI healthcare initiatives.
PA GoodDoctor (01833): CLSA believes that the performance of PA GoodDoctor's stock price can be attributed to its progress in medical AI and an improved profit outlook. It is expected that the flourishing development of AI healthcare empowerment and commercial health insurance will drive further growth for the company.